|
業務類別
|
Biotechnology |
|
業務概覽
|
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets. |
| 公司地址
| 300 Fifth Avenue, Waltham, MA, USA, 02451 |
| 電話號碼
| +1 617 430-5595 |
| 傳真號碼
| +1 301 738-2137 |
| 公司網頁
| https://www.crescentbiopharma.com |
| 員工數量
| 44 |
| Ms. Barbara Bispham |
General Counsel and Corporate Secretary |
-- |
21/04/2026 |
| Mr. Joshua T. Brumm |
Chief Executive Officer and Director |
美元 554.17K |
21/04/2026 |
| Mr. Richard William Scalzo |
Chief Financial Officer |
-- |
21/04/2026 |
| Dr. Ellie Im, M.D. |
Chief Medical Officer |
美元 401.25K |
21/04/2026 |
| Dr. Jan Pinkas, PhD |
Chief Scientific Officer |
-- |
21/04/2026 |
| Mr. Ryan Lynch |
Chief Accounting Officer, Treasurer and Senior Vice President, Finance |
美元 19.40K |
21/04/2026 |
| Dr. Jonathan McNeill, M.D. |
Chief Operating Officer and President |
美元 435.42K |
21/04/2026 |
|
|
| Ms. Alexandra Balcom, C.P.A.,M.B.A. |
Independent Director |
21/04/2026 |
| Dr. Susan Moran, M.D. |
Independent Director |
21/04/2026 |
| Mr. David Charles Lubner, C.P.A.,M.S. |
Independent Director |
21/04/2026 |
| Mr. Joshua T. Brumm |
Chief Executive Officer and Director |
21/04/2026 |
| Mr. Peter Harwin |
Chairman of the Board |
21/04/2026 |
| Dr. Jonathan Violin, M.B.A.,PhD |
Director |
21/04/2026 |
|
|
|
|
